Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 29, 2026, 4:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 201 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Stage IA Breast Cancer AJCC v7 Clear all
Recruiting Not applicable Interventional

Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy

NCT02945579
View directory record Official record
Conditions
Estrogen Receptor Negative, HER2 Positive Breast Carcinoma, HER2/Neu Negative, Invasive Breast Carcinoma, Progesterone Receptor Negative, Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Triple-Negative Breast Carcinoma
Interventions
Undergo EBRT, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Questionnaire Administration, Partial Breast Irradiation
Radiation · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
30 Years and older · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
8
States / cities
Gilbert, Arizona • Jacksonville, Florida • Honolulu, Hawaii + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Sep 29, 2026, 4:14 PM EDT
Completed No phase listed Observational

Treatment Decision Making in African American Women Diagnosed With Triple Negative Breast Cancer

NCT05071677
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Invasive Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Triple-Negative Breast Carcinoma
Interventions
Discussion, Interview, Survey Administration
Procedure · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 8, 2023 · Synced Sep 29, 2026, 4:14 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Multiscale Omics for the Development of a Cohort Database and Study Platform in Breast Cancer Survivors

NCT04999826
View directory record Official record
Conditions
Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage 0 Breast Cancer AJCC v8, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8
Interventions
Biospecimen Collection, Quality-of-Life Assessment, Questionnaire Administration
Procedure · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 29, 2025 · Synced Sep 29, 2026, 4:14 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery

NCT01349322
View directory record Official record
Conditions
Breast Cancer
Interventions
Standard fractionation whole breast irradiation, Hypofractionated whole breast irradiation, Concurrent boost, Sequential boost
Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older · Female only
Enrollment
2,354 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
386
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 304 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Sep 29, 2026, 4:14 PM EDT
Terminated Phase 1 Interventional

RBX7455 Before Surgery for the Treatment of Operable Breast Cancer

NCT04139993
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Breast Adenocarcinoma, Invasive Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Triple-Negative Breast Carcinoma
Interventions
Microbiota-based Formulation RBX7455
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 3, 2023 · Synced Sep 29, 2026, 4:14 PM EDT
Active, not recruiting Not applicable Interventional

Intraoperative Radiation Therapy in Treating Patients With Breast Cancer Undergoing Breast-Conserving Surgery

NCT01570998
View directory record Official record
Conditions
Stage IA Breast Cancer, Stage IIA Breast Cancer
Interventions
Intraoperative Radiation Therapy, Laboratory Biomarker Analysis
Radiation · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
45 Years and older · Female only
Enrollment
1,259 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2028
U.S. locations
25
States / cities
Berkeley, California • Irvine, California • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Sep 29, 2026, 4:14 PM EDT
Completed Not applicable Interventional

Development of a Questionnaire to Evaluate Patient Expectations for Breast Reconstruction in Women With Breast Cancer or Other Conditions

NCT00471601
View directory record Official record
Conditions
Breast Cancer
Interventions
counseling intervention, questionnaire administration, psychosocial assessment and care, quality-of-life assessment
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
357 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2023
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 1, 2024 · Synced Sep 29, 2026, 4:14 PM EDT
Completed No phase listed Observational

S9313A Protein Expression Analysis of Breast Cancer Tissue Microarrays From Clinical Trial SWOG-9313

NCT00896727
View directory record Official record
Conditions
Breast Cancer
Interventions
gene expression analysis, protein expression analysis, fluorescent antibody technique, laboratory biomarker analysis
Genetic · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older · Female only
Enrollment
2,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 19, 2019 · Synced Sep 29, 2026, 4:14 PM EDT
Completed Phase 2 Interventional

Oxaloacetate for the Improvement of Cognitive Complaints in Stage 0-IIIA Breast Cancer Survivors

NCT04290897
View directory record Official record
Conditions
Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Early-Stage Breast Carcinoma, Prognostic Stage 0 Breast Cancer AJCC v8, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8
Interventions
Anhydrous Enol-oxaloacetate, Questionnaire Administration
Drug · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years to 74 Years · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 14, 2025 · Synced Sep 29, 2026, 4:14 PM EDT
Completed Not applicable Interventional

Multimedia Educational Program for Patients With Early-Stage Prostate Cancer or Breast Cancer

NCT00830635
View directory record Official record
Conditions
Breast Cancer, Depression, Long-term Effects of Cancer Treatment, Prostate Cancer, Psychosocial Effects of Cancer and Its Treatment
Interventions
educational intervention, informational intervention, internet-based intervention, questionnaire administration, study of socioeconomic and demographic variables, survey administration, psychosocial assessment and care, quality-of-life assessment
Other · Procedure
Lead sponsor
University of Colorado, Denver
Other
Eligibility
Not listed
Enrollment
1,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
3
States / cities
Miami, Florida • New York, New York • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 15, 2015 · Synced Sep 29, 2026, 4:14 PM EDT
Completed Phase 2 Interventional Results available

Study of Docosahexaenoic Acid (DHA) in Triple Negative Breast Cancer Survivors

NCT01849250
View directory record Official record
Conditions
Benign Breast Neoplasm, Ductal Breast Carcinoma In Situ, Invasive Breast Carcinoma, Lobular Breast Carcinoma In Situ, Paget Disease of the Breast, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
Docosahexaenoic Acid, Placebo
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
4
States / cities
Boston, Massachusetts • New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 27, 2021 · Synced Sep 29, 2026, 4:14 PM EDT
Completed Phase 2 Interventional Results available

Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Breast Cancer

NCT01750073
View directory record Official record
Conditions
Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative, HER2/Neu Positive, Invasive Breast Carcinoma, Progesterone Receptor Negative, Progesterone Receptor Positive, Stage IA Breast Cancer, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Triple-Negative Breast Carcinoma
Interventions
Cyclophosphamide, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Paclitaxel, Radiation Therapy, Therapeutic Conventional Surgery, Trastuzumab
Drug · Other · Radiation + 2 more
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older · Female only
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2025
U.S. locations
4
States / cities
Bellevue, Nebraska • Grand Island, Nebraska • Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Sep 29, 2026, 4:14 PM EDT
Completed Phase 1 Interventional

Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors

NCT01522820
View directory record Official record
Conditions
Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Anaplastic Oligodendroglioma, Estrogen Receptor Negative, Estrogen Receptor Positive, Glioblastoma, Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma, Metastatic Renal Cell Cancer, Recurrent Adult Brain Neoplasm, Recurrent Bladder Carcinoma, Recurrent Breast Carcinoma, Recurrent Colorectal Carcinoma, Recurrent Esophageal Carcinoma, Recurrent Gastric Carcinoma, Recurrent Hepatocellular Carcinoma, Recurrent Lung Carcinoma, Recurrent Melanoma, Recurrent Ovarian Carcinoma, Recurrent Prostate Carcinoma, Recurrent Renal Cell Carcinoma, Recurrent Uterine Corpus Carcinoma, Resectable Hepatocellular Carcinoma, Sarcoma, Stage IA Breast Cancer, Stage IA Ovarian Cancer, Stage IA Uterine Corpus Cancer, Stage IB Breast Cancer, Stage IB Ovarian Cancer, Stage IB Uterine Corpus Cancer, Stage IC Ovarian Cancer, Stage II Uterine Corpus Cancer, Stage IIA Breast Cancer, Stage IIA Lung Carcinoma, Stage IIA Ovarian Cancer, Stage IIB Breast Cancer, Stage IIB Esophageal Cancer, Stage IIB Lung Carcinoma, Stage IIB Ovarian Cancer, Stage IIB Skin Melanoma, Stage IIC Ovarian Cancer, Stage IIC Skin Melanoma, Stage IIIA Breast Cancer, Stage IIIA Esophageal Cancer, Stage IIIA Lung Carcinoma, Stage IIIA Ovarian Cancer, Stage IIIA Skin Melanoma, Stage IIIA Uterine Corpus Cancer, Stage IIIB Breast Cancer, Stage IIIB Esophageal Cancer, Stage IIIB Ovarian Cancer, Stage IIIB Skin Melanoma, Stage IIIB Uterine Corpus Cancer, Stage IIIC Breast Cancer, Stage IIIC Esophageal Cancer, Stage IIIC Ovarian Cancer, Stage IIIC Skin Melanoma, Stage IIIC Uterine Corpus Cancer, Stage IV Bladder Urothelial Carcinoma, Stage IV Esophageal Cancer, Stage IV Ovarian Cancer, Stage IV Prostate Cancer, Stage IV Skin Melanoma, Stage IVA Uterine Corpus Cancer, Stage IVB Uterine Corpus Cancer
Interventions
DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Laboratory Biomarker Analysis, Pharmacological Study, Sirolimus
Biological · Other · Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Oct 3, 2016 · Synced Sep 29, 2026, 4:14 PM EDT
Completed Not applicable Interventional

Omega-3 Fatty Acids in Preventing Joint Symptoms in Patients With Stage I-III Breast Cancer Receiving Anastrozole, Exemestane, or Letrozole

NCT01478477
View directory record Official record
Conditions
Recurrent Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
omega-3 fatty acid supplement, Placebo, Clinical assessments, Assessment of therapy complications, Magnetic Resonance Imaging, Correlative/special studies
Dietary Supplement · Other · Procedure
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 26, 2023 · Synced Sep 29, 2026, 4:14 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Functional Magnetic Resonance Imaging in Assessing Affect Reactivity and Regulation in Patients With Stage 0-III Breast Cancer

NCT03050463
View directory record Official record
Conditions
Healthy Subject, Stage 0 Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
Biospecimen Collection, Functional Magnetic Resonance Imaging, Questionnaire Administration
Procedure · Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older · Female only
Enrollment
178 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jul 26, 2022 · Synced Sep 29, 2026, 4:14 PM EDT
Completed Not applicable Interventional

Patient Reported Outcomes, Smart Pill Bottle and Teleheath for Endocrine Therapy Adherence

NCT04054557
View directory record Official record
Conditions
Stage 0 Breast Cancer AJCC v6 and v7, Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage III Breast Cancer AJCC v7
Interventions
Telemedicine, Best Practice, Questionnaire Administration, Quality-of-Life Assessment, Survey Administration, Behavioral Intervention, Educational Intervention
Other · Behavioral
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
5
States / cities
Washington Township, New Jersey • Philadelphia, Pennsylvania • Torresdale, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Sep 29, 2026, 4:14 PM EDT
Active, not recruiting Phase 2 Interventional

Radiation Therapy in Treating Patients With Stage 0-II Breast Cancer

NCT01245712
View directory record Official record
Conditions
Breast Adenocarcinoma, Ductal Breast Carcinoma In Situ, Invasive Breast Carcinoma, Stage 0 Breast Cancer AJCC v6 and v7, Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7
Interventions
Accelerated Partial Breast Irradiation, Proton Beam Radiation Therapy, Quality-of-Life Assessment
Radiation · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2032
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Sep 29, 2026, 4:14 PM EDT
Terminated Not applicable Interventional Results available

Biomarkers in Tissue Samples From Patients With Newly Diagnosed Breast Cancer Treated With Zoledronic Acid

NCT01409811
View directory record Official record
Conditions
Estrogen Receptor-positive Breast Cancer, Invasive Ductal Breast Carcinoma, Progesterone Receptor-positive Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer
Interventions
zoledronic acid, laboratory biomarker analysis, therapeutic conventional surgery
Drug · Other · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
Female only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated May 7, 2020 · Synced Sep 29, 2026, 4:14 PM EDT
Completed Not applicable Interventional

Computerized Cognitive Retraining in Improving Cognitive Function in Breast Cancer Survivors

NCT02662335
View directory record Official record
Conditions
Cancer Survivor, Stage 0 Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
Computer-Assisted Cognitive Training, Questionnaire Administration, Standard Follow-Up Care
Other · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 12, 2017 · Synced Sep 29, 2026, 4:14 PM EDT
Completed Not applicable Interventional

S1200: Acupuncture, Sham Acupuncture, or Wait List for Joint Symptoms Related to Aromatase Inhibitors in Pts W/Early-Stage Breast Cancer

NCT01535066
View directory record Official record
Conditions
Breast Cancer, Pain
Interventions
acupuncture therapy, sham acupuncture
Procedure
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older · Female only
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
47
States / cities
Antioch, California • Fremont, California • Los Angeles, California + 36 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2022 · Synced Sep 29, 2026, 4:14 PM EDT
Completed Phase 3 Interventional Results available

Testosterone in Treating Postmenopausal Patients With Arthralgia Caused by Adjuvant Aromatase Inhibitor Treatment

NCT01573442
View directory record Official record
Conditions
Arthralgia, Breast Cancer, Hot Flashes, Musculoskeletal Complications, Sexual Dysfunction
Interventions
testosterone, placebo
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
528
States / cities
Anchorage, Alaska • Hot Springs, Arkansas • Auburn, California + 331 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2025 · Synced Sep 29, 2026, 4:14 PM EDT
Completed Phase 3 Interventional Results available

Letrozole in Preventing Cancer in Postmenopausal Women Who Have Received 4-6 Years of Hormone Therapy for Hormone Receptor-Positive, Lymph Node-Positive, Early-Stage Breast Cancer

NCT00553410
View directory record Official record
Conditions
Breast Cancer
Interventions
Letrozole
Drug
Lead sponsor
ETOP IBCSG Partners Foundation
Network
Eligibility
18 Years to 120 Years · Female only
Enrollment
4,884 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2019
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 29, 2026, 4:14 PM EDT
Terminated Phase 1 Interventional Results available

Retinoid 9cUAB30 in Producing a Biologic Effect in Patients With Early Stage Breast Cancer

NCT02876640
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Breast Ductal Carcinoma In Situ, Early Stage Breast Carcinoma, Invasive Breast Carcinoma
Interventions
Biospecimen Collection, Retinoid 9cUAB30, Therapeutic Conventional Surgery
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
5
States / cities
Birmingham, Alabama • Chicago, Illinois • Iowa City, Iowa + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2024 · Synced Sep 29, 2026, 4:14 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Blood Sample Collection and Health Information Collection From Patients With Invasive Breast Cancer and Their Brothers and Sisters

NCT00445562
View directory record Official record
Conditions
Breast Cancer
Interventions
biologic sample preservation procedure, informational intervention
Other
Lead sponsor
GenBasix Incorporated
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2001
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jul 9, 2013 · Synced Sep 29, 2026, 4:14 PM EDT